These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31748715)

  • 1. Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression.
    Hu L; Sun Y; Luo J; He X; Ye M; Li G; Zhang Y; Bai J; Zhang D; Chang C
    Oncogene; 2020 Feb; 39(9):1891-1903. PubMed ID: 31748715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.
    Yang DR; Ding XF; Luo J; Shan YX; Wang R; Lin SJ; Li G; Huang CK; Zhu J; Chen Y; Lee SO; Chang C
    J Biol Chem; 2013 Jun; 288(23):16476-16483. PubMed ID: 23609451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
    Zhu J; Qin P; Cao C; Dai G; Xu L; Yang D
    Oncol Rep; 2021 Mar; 45(3):963-974. PubMed ID: 33650661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A; Kim SH; Hwang C
    Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer.
    Chen B; Yu S; Ding X; Jing C; Xia L; Wang M; Matro E; Rehman F; Niu Y; Li G; Chang C
    Cancer Gene Ther; 2014 Oct; 21(10):411-5. PubMed ID: 25104727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.
    Shen J; Lin H; Li G; Jin RA; Shi L; Chen M; Chang C; Cai X
    Oncotarget; 2016 May; 7(22):32088-99. PubMed ID: 27050071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity.
    Chen D; Chou FJ; Chen Y; Tian H; Wang Y; You B; Niu Y; Huang CP; Yeh S; Xing N; Chang C
    Cancer Lett; 2020 Dec; 495():100-111. PubMed ID: 32768524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.
    Festuccia C; Mancini A; Gravina GL; Colapietro A; Vetuschi A; Pompili S; Ventura L; Delle Monache S; Iorio R; Del Fattore A; Fogler W; Magnani J
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
    Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C
    Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
    Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
    Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
    Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small ankyrin 1 (sANK1) promotes docetaxel resistance in castration-resistant prostate cancer cells by enhancing oxidative phosphorylation.
    Yang Y; Qin H; Ding M; Ji C; Chen W; Diao W; Yin H; Chen M; Gan W; Guo H
    FEBS Open Bio; 2023 Feb; 13(2):257-269. PubMed ID: 36508323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin.
    Bouaouiche S; Magadoux L; Dondaine L; Reveneau S; Isambert N; Bettaieb A; Jeannin JF; Laurens V; Plenchette S
    Int J Oncol; 2019 Apr; 54(4):1446-1456. PubMed ID: 30720069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
    Babasaki T; Sentani K; Sekino Y; Kobayashi G; Thang Pham Q; Katsuya N; Akabane S; Taniyama D; Hayashi T; Shiota M; Oue N; Teishima J; Matsubara A; Yasui W
    Cancer Med; 2021 Aug; 10(16):5574-5588. PubMed ID: 34240817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβR2/p-Smad3 signals.
    Qiu X; Zhu J; Sun Y; Fan K; Yang DR; Li G; Yang G; Chang C
    Oncotarget; 2015 Jun; 6(17):15397-409. PubMed ID: 25980442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of a retinoid X receptor-selective ligand bexarotene and docetaxel in prostate cancer.
    Shen D; Wang H; Zheng Q; Cheng S; Xu L; Wang M; Li GH; Xia LQ
    Onco Targets Ther; 2019; 12():7877-7886. PubMed ID: 31576145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism.
    Chen L; Song Y; Hou T; Li X; Cheng L; Li Y; Xing Y
    J Exp Clin Cancer Res; 2022 Jun; 41(1):194. PubMed ID: 35659274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT-20 cells.
    Xia L; Shen D; Zhang Y; Lu J; Wang M; Wang H; Chen Y; Xue D; Xie D; Li G
    J Cell Mol Med; 2021 Mar; 25(5):2404-2417. PubMed ID: 33491272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer.
    Sarwar S; Morozov VM; Newcomb MA; Yan B; Brant JO; Opavsky R; Guryanova OA; Ishov AM
    Cell Death Dis; 2024 Aug; 15(8):558. PubMed ID: 39090086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.